Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial

Inclusion Criteria: * HIV infection (verified by previous positive antibody or detectable HIV RNA level) * Age \> 50 years * Receiving continuous ART for \>= 2 years (regimen changes \> 6 months prior to enrollment are allowed) * HIV RNA level \< 200 copies/mL for \>= 1 year (1 measure \>= 200 allowed if also \< 1000 and preceded and followed by values \< 200 copies/mL) * Blood CD4+ T-cell count \< 600 cells/mm cubed * Systolic blood pressure \> 120 mmHg (mean value if \>= 2 measures obtained) * Estimated glomerular filtration rate (GFR )\> 30 mL/min/1.73 m squared * Do not anticipate starting or stopping statin or aspirin therapy during the study Exclusion Criteria: * Pregnancy or breastfeeding * A contra-indication to taking an angiotensin receptor blocker (ARB) (e.g., cirrhosis, prior angioedema with angiotensin-converting enzyme inhibitor (ACE-I), or use of drug with potential drug-interaction \[e.g., rifaximin\]) * A clinical indication for ARB or ACE-I therapy (e.g., cardiovascular disease (CVD), stroke, or diabetes mellitus (DM)) * Current treatment with ARB or medication with overlapping mechanism (e.g., ACE-I or aldosterone antagonist) * Current treatment with immunomodulatory drugs within the past 6 months * Current hepatitis treatments (e.g., interferon, ribavirin) within the past 6 months * Serum potassium \> 5.0 millimoles per liter (mmol/L) within 3 months of entry * Invasive cancer in the prior year or receiving cancer treatment (not including carcinoma-in-situ or basal cell cancer of the skin) * Cirrhosis or end-stage liver disease * Rheumatologic or chronic inflammatory disease (e.g., systematic lupus erythematous, psoriasis, rheumatoid arthritis, vasculitis, sarcoidosis, Crohn's disease)